Photo by nci from unsplash
Key Points Question Does hyperthermic intraperitoneal chemotherapy (HIPEC) after primary or interval cytoreductive surgery increase survival in patients with ovarian cancer? Findings In this randomized clinical trial of 184 women… Click to show full abstract
Key Points Question Does hyperthermic intraperitoneal chemotherapy (HIPEC) after primary or interval cytoreductive surgery increase survival in patients with ovarian cancer? Findings In this randomized clinical trial of 184 women with ovarian cancer, among those who underwent interval cytoreductive surgery after neoadjuvant chemotherapy, the addition of HIPEC decreased recurrence and increased overall survival; however, in patients undergoing primary cytoreductive surgery, progression-free survival and overall survival were not improved. No unresolved serious HIPEC-related adverse events were found in either group. Meaning These results suggest that HIPEC after interval cytoreductive surgery may increase progression-free and overall survival in patients with ovarian cancer who receive neoadjuvant chemotherapy.
Journal Title: JAMA Surgery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!